Drugs / Itopride
Itopride
also known as
Ganaton · Itopride HCI · Itoprida · Itopride HCL · itopride hydrochloride · NSC-759643
Small molecule targets ACHE, DRD2 via inhibition
Trials 15
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/22 trials | ||||||
| Phase 1/2 | NCT00370110 | Aug → Nov 2005 | — | Forest Laboratories | Completed | No outcome recorded |
| Phase 1/2 | NCT00370084 | Mar 2005 → May 2006 | gastroparesis | Forest Laboratories | Completed | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT05966025 | Dec 2023 → Dec 2024 | metabolic dysfunction-associated steatotic liver disease | October 6 University | Unknown | No outcome recorded |
| Phase 2/32 trials | ||||||
| Phase 2/3 | NCT00308399 | Nov 2005 → Jun 2007 | — | Mayo Clinic | Completed | No outcome recorded |
| Phase 2/3 | NCT00272103 | Dec 2000 → Jan 2002 | dyspepsia | Royal Adelaide Hospital | Completed | No outcome recorded |
| Phase 36 trials | ||||||
| Phase 3 | NCT04161768 | Dec 2018 → Dec 2028 expected | infectious peritonitis | Tanta University | Recruiting | No outcome recorded |
| Phase 3 | NCT00382577 | Oct → Dec 2006 | dyspepsia | Forest Laboratories | Completed | No outcome recorded |
| Phase 3 | NCT00112203 | Nov 2004 → Jul 2006 | dyspepsia | Forest Laboratories | Completed | No outcome recorded |
| Phase 3 | NCT00110968 | Sep 2004 → Jul 2006 | dyspepsia | Forest Laboratories | Completed | No outcome recorded |
| Phase 3 | NCT00112190 | Jul 2004 → Mar 2005 | dyspepsia | Forest Laboratories | Completed | No outcome recorded |
| Phase 3 | NCT00112177 | Jul 2004 → Aug 2006 | dyspepsia | Forest Laboratories | Completed | No outcome recorded |
| Phase 43 trials · 2 missed | ||||||
| Phase 4 | NCT07031479 | Jul 2025 → Jun 2026 overdue | — | Chulalongkorn University | Not yet recruiting | No outcome recorded |
| Phase 4 | NCT04918017 | Nov 2021 → Dec 2023 | dyspepsia | University of Malaya | Unknown | Missed primary |
| Phase 4 | NCT04647955 | Feb 2013 → Oct 2015 | dyspepsia | Universitaire Ziekenhuizen KU Leuven | Completed | Missed primary |
| Phase not applicable1 trial | ||||||
| — | NCT01226134 | Feb 2009 → Mar 2011 | dyspepsia | Aga Khan University | Unknown | No outcome recorded |
| Comparator or background therapy14 trials | ||||||
| Phase 2 | NCT01513811 Comparator | Feb 2010 → Nov 2011 | constipation disorder | Shanghai Jiao Tong University School of Medicine | Completed | No outcome recorded |
| Phase 2 | NCT01027260 Comparator | Jun 2008 → Aug 2010 | irritable bowel syndrome | Abbott | Completed | No outcome recorded |
| Phase 3 | NCT07174297 Comparator | Oct 2025 → Dec 2026 expected | — | Getz Pharma | Not yet recruiting | No outcome recorded |
| Phase 3 | NCT06217393 Comparator | Feb 2024 → Feb 2025 | dyspepsia | Abbott | Completed | No outcome recorded |
| Phase 3 | NCT01513096 Comparator | Nov 2011 → Jan 2012 | — | Inje University | Completed | No outcome recorded |
| Phase 4 | NCT07449689 Comparator | Apr → Dec 2026 expected | dyspepsia | Aga Khan University | Not yet recruiting | No outcome recorded |
| Phase 4 | NCT07254715 Comparator | Jan → Jul 2026 | — | Ain Shams University | Completed | No outcome recorded |
| Phase 4 | NCT05134584 Background | Jan → Dec 2021 | dyspepsia, irritable bowel syndrome | RenJi Hospital | Unknown | Met primary |
| Phase 4 | NCT04464369 Comparator | Sep 2013 → Nov 2016 | dyspepsia | Universitaire Ziekenhuizen KU Leuven | Completed | No outcome recorded |
| — | NCT04104867 Comparator | Sep 2019 → Oct 2022 | — | Mahidol University | Unknown | No outcome recorded |
| — | NCT04572932 Comparator | May → Dec 2019 | irritable bowel syndrome | Ain Shams University | Completed | No outcome recorded |
| — | NCT03698292 Comparator | Oct 2018 → Jun 2019 | — | Ain Shams University | Unknown | No outcome recorded |
| — | NCT04697641 Comparator | Sep 2017 → May 2019 | Helicobacter pylori infectious disease, dyspepsia | Sir Ganga Ram Hospital | Completed | Missed primary |
| — | NCT00599677 Comparator | Nov 2007 → Sep 2009 | dyspepsia | Chengdu University of Traditional Chinese Medicine | Completed | No outcome recorded |
Evidence & citations 12 cited values
Every value below carries the sentence it was read from. 31 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Itopride | “first group was prescribed probiotics (10 billion colony of lactobacillus delbruekii and lactobacillus fermentum) and itopride hcl 50mg three times daily for 4 weeks” NCT04572932 ↗28“Acotiamide versus Itopride in patient with post prandial distress syndrome type of functional dyspepsia” NCT07174297 ↗ |
| Known as | Ganaton | “Itopride is a new compound that is already marketed in Japan and in some countries of Eastern Europe under the name of Ganaton.” NCT00370110 ↗5“Itopride is a new compound that is already marketed in Japan and in some countries of Eastern Europe under the name of Ganaton.” NCT00370084 ↗ “Itopride is a new compound that is already marketed in Japan and in some countries of Eastern Europe under the name of Ganaton.” NCT00112190 ↗ “Itopride is a new compound that is already marketed in Japan and in some countries of Eastern Europe under the name of Ganaton.” NCT00112177 ↗ “Itopride is a compound already marketed in Japan and in some countries of Eastern Europe under the name of Ganaton.” NCT00112203 ↗ “Itopride is a compound already marketed in Japan and in some countries of Eastern Europe under the name of Ganaton.” NCT00110968 ↗ |
| Known as | Itoprida | ChEMBL registry synonym — accepted as the source's own label CHEMBL2107457 ↗ |
| Known as | Itopride HCI | “Drug: Itopride HCI 50 mg” NCT07031479 ↗1“Itopride HCI 50 mg” NCT07254715 ↗ |
| Known as | Itopride HCL | “Itopride HCL” NCT07254715 ↗ |
| Known as | itopride hydrochloride | “The primary objective of this study is to evaluate the acute effects of itopride hydrochloride (200 mg three times daily) on gastric emptying of solid and liquid meal...” NCT00370084 ↗ |
| Known as | NSC-759643 | ChEMBL registry synonym — accepted as the source's own label CHEMBL2107457 ↗ |
| Action | Inhibit | “acts via dopamine D2 receptor antagonism and acetylcholinesterase inhibition” PMID 39989849 ↗ Feb 2025 |
| Modality | Small molecule | — CHEMBL2107457 ↗ |
| Route | Oral | “30 minutes after ingestion of study medication” NCT00308399 ↗ |
| Target | ACHE | “Acetylcholinesterase inhibitor” CHEMBL2107457 ↗ |
| Target | DRD2 | “Dopamine D2 receptor antagonist” CHEMBL2107457 ↗ |